Celgene buoyant on positive pancreatic cancer Phase III and filing plans for Abraxane
This article was originally published in Scrip
Executive Summary
Celgene's announcement of plans to file for approval of Abraxane (paclitaxel protein-bound particles for injectable suspension; albumin bound) for pancreatic cancer in the US, Europe and other markets saw the company's share price rise by more than 9%.